Navigation Links
Delcath to Present at Upcoming Investor Conferences
Date:3/2/2011

NEW YORK, March 2, 2011 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) announced today that executive management will present an overview of the Company's business strategy and recent corporate developments at the following investor conferences:

  • The Cowen and Company Healthcare Conference in Boston.  Mr. Eamonn Hobbs, Chief Executive Officer, and Mr. David McDonald, Chief Financial Officer, are scheduled to present an overview of the Company on Tuesday, March 8, 2011 at 10:15 a.m. ET.
  • ROTH Capital Annual OC Growth Stock Conference in Laguna Niguel, California.  Mr. Hobbs is scheduled to present an overview of the Company on Monday, March 14, 2011 at 1:30 p.m. PT.

  • Attendance at each of these conferences is by invitation only. Delcath will offer live and audio webcasts of its presentation, which may be accessed on the Investor Relations section of the Company's website at www.delcath.com.  An archived replay of the presentations will be available for 90 days, also at www.delcath.com.

    About Delcath SystemsDelcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath concluded a Phase III metastatic melanoma study, and the Company recently completed a multi-arm Phase II trial to treat other liver cancers. The Company has not yet received FDA or any foreign regulatory approval for commercial sale of its system. For more information, please visit the Company's website at www.delcath.com.

    The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward–looking statements made by the Company or on its behalf. This news release contains forward–looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward–looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward–looking statements to reflect events or circumstances after the date they are made.Contact Information:Investor Contact:

    Media Contact:Gregory Gin/Doug Sherk

    Janine McCargoEVC Group

    EVC Group646-445-4801/415-896-6818

    646-688-0425
    '/>"/>

    SOURCE Delcath Systems, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Delcath Systems Receives Refusal to File Letter From FDA
    2. Delcath Achieves ISO 13485 Certification
    3. Delcath Completes New Drug Application Submission to the FDA for the Chemosaturation Delivery System
    4. Delcath Systems Announces Third Quarter Progress Report Conference Call
    5. Delcath Strengthens Research and Development Team with Key Appointments
    6. Delcath Signs Agreement With Synerx and Mylans Bioniche Teoranta for Melphalan Supply
    7. Delcath to Present at the William Blair Emerging Growth Stock Conference
    8. Delcath to Present at the JMP Securities Healthcare Conference
    9. Delcath Systems Announces Completion of Common Stock Offering
    10. Delcath to Present at the 30th Annual Canaccord Global Growth Conference
    11. Delcath to Present at the 2010 Wedbush Securities Life Sciences Best Ideas Management Access Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/16/2017)... , Jan 16, 2017 Research and Markets ... Market 2017-2021" report to their offering. ... Global multiple myeloma drugs market to ... The report covers the present scenario and the growth ... calculate the market size, the report considers the revenue generated from ...
    (Date:1/16/2017)... , Jan. 16, 2017 Research and Markets ... Market Analysis, Market Size, Test Analysis, Country Outlook, Growth Potential, Competitive ... ... 2.5 Million tests will be conducted by the 11 major NIPT ... research report presents a comprehensive assessment of the market and contains ...
    (Date:1/16/2017)...  An aneurysm develops due to the weakening of blood ... can occur in any artery, it happens most often in ... to legs. Most aortic aneurysms occur in the section of ... as abdominal aortic aneurysms, sometimes in the chest referred as ... the abdomen is about 2 cm but in the case ...
    Breaking Medicine Technology:
    (Date:1/16/2017)... Mesa, California (PRWEB) , ... January 16, 2017 , ... ... 2014, Dr. Beazley has served on CalSouthern’s Board of Trustees and as a core ... In addition, he has been a professor of psychology at Pepperdine University, where he ...
    (Date:1/16/2017)... (PRWEB) , ... January 16, 2017 , ... Gym Source, ... of a new showroom in East Hanover, New Jersey. , “We are elated to ... “The new innovative in-store concept is designed to give clients a seamless and motivating ...
    (Date:1/16/2017)... , ... January 16, 2017 , ... ... will demonstrate their groundbreaking GunSport•PRO® and EB15•LE® electronic earplugs at the NSSF SHOT ... Las Vegas, Booth #2809. The SHOT Show is the shooting, hunting and outdoor ...
    (Date:1/16/2017)... Lake, Utah (PRWEB) , ... January 16, 2017 , ... ... (UAC) officially opened on January 8 for use by sports teams and the general ... full, indoor volleyball courts that can also be converted into basketball or pickleball courts. ...
    (Date:1/16/2017)... ... January 16, 2017 , ... Anybody who may be looking for a substance ... released by Serenity Recovery, a holistic treatment center for addiction located in Marne, MI. ... and testimonials from patients and staff that visited the 2016 Recovery Palooza support event ...
    Breaking Medicine News(10 mins):